one
primari
goal
success
cancer
treatment
regimen
deliv
suffici
amount
drug
tumor
minim
damag
normal
tissu
chemotherapeut
agent
enter
normal
tissu
bodi
indiscrimin
cytotox
preferenti
accumul
tumor
site
time
dose
reach
tumor
may
littl
dose
accumul
normal
organ
one
reason
inabl
drug
accumul
target
site
interstiti
fluid
pressur
ifp
solid
tumor
higher
normal
tissu
block
transcapillari
transport
chemotherapeut
drug
antibodi
way
anticanc
effect
decreas
toxic
effect
normal
cell
increas
fear
sever
harm
patient
often
limit
dose
anticanc
drug
given
patient
lower
optim
dose
elicit
incomplet
tumor
respons
lead
diseas
relaps
drug
resist
therefor
cancer
drug
fail
clinic
studi
ineffect
kill
cancer
cell
administ
dose
high
enough
erad
tumor
without
sever
harm
patient
sever
approach
develop
improv
abil
anticanc
drug
specif
target
tumor
avoid
normal
organ
one
effect
strategi
encapsul
drug
particl
deliv
preferenti
tumor
site
exampl
liposom
particl
found
abl
deliv
radionuclid
gene
chemotherapeut
agent
tumor
site
anoth
promis
strategi
encapsul
anticanc
drug
liposom
conjug
moieti
antibodi
peptid
target
particular
type
target
tumor
cell
tumor
vasculatur
use
intern
ligand
target
liposom
conjug
moieti
make
possibl
deliv
chemotherapeut
drug
encapsul
within
cytosol
receptormedi
endocytosi
articl
review
current
research
develop
liposom
drug
deliveri
system
use
peptid
ligand
target
blood
vessel
solid
tumor
discuss
identif
peptid
target
tumor
blood
vessel
use
target
nontarget
liposom
encapsul
deliv
chemotherapeut
drug
tumor
site
virtual
everi
convent
cytotox
drug
found
antiangiogen
vitro
vivo
model
one
treatment
approach
known
metronom
therapi
use
frequent
administr
lowdos
antiangiogen
agent
destroy
vessel
tumor
decreas
toxic
normal
tissu
exampl
found
mice
frequent
administr
rel
low
noncytotox
dose
liposomeencapsul
doxorubicin
shrink
variou
solid
tumor
xenograft
antiangiogen
agent
bevacizumab
avastin
human
monoclon
antibodi
vascular
endotheli
growth
factor
vegf
use
success
treat
advanc
colon
cancer
one
studi
compar
effect
use
three
chemotherapeut
agent
alon
treat
advanc
colon
cancer
use
three
agent
combin
bevacizumab
found
combin
use
chemotherapeut
agent
bevacizumab
extend
overal
surviv
approxim
month
compar
use
chemotherapeut
agent
alon
angiogenesi
inhibitor
includ
sunitinib
sorafenib
also
found
improv
clinic
outcom
use
treat
variou
cancer
type
target
prolifer
endotheli
cell
blood
vessel
tumor
sever
advantag
first
endotheli
cell
malign
tumor
genet
stabl
nonmalign
rare
drug
resist
compar
cancer
cell
howev
recent
studi
show
tumorassoci
endotheli
cell
acquir
cytogenet
abnorm
tumor
microenviron
second
destruct
endotheli
cell
use
method
amplifi
drug
antitumor
effect
report
elimin
one
endotheli
cell
inhibit
growth
mani
hundr
tumor
cell
third
antiangiogen
therapi
decreas
ifp
within
tumor
allow
better
penetr
chemotherapeut
agent
exampl
jain
found
bevacizumab
could
decreas
ifp
normal
tumor
vasculatur
decreas
vascular
leakag
fourth
antiangiogen
therapi
known
inhibit
growth
primari
metastat
solid
tumor
final
intraven
inject
angiogenesi
inhibitor
directli
reach
endotheli
cell
addit
take
advantag
differ
endotheli
cell
plasma
membran
protein
ie
vascular
zip
code
develop
drug
deliveri
system
capabl
guid
therapeut
imag
agent
particular
organ
tumor
endotheli
cell
blood
vessel
within
solid
tumor
express
certain
molecular
structur
absent
minim
detect
normal
blood
vessel
structur
use
molecular
target
antitumor
treatment
key
deliv
drug
specif
target
identifi
use
ligand
specif
bind
intern
endotheli
cell
tumor
combinatori
peptid
librari
display
microorgan
becom
research
tool
identifi
cell
surfacebind
peptid
becom
target
antitumor
treatment
mani
molecular
display
techniqu
phage
display
popular
approach
phage
display
select
techniqu
peptid
protein
fuse
coat
protein
bacteriophag
display
surfac
virion
phagedisplay
random
peptid
librari
help
research
map
bcell
epitop
discov
proteinprotein
contact
identifi
bioactiv
peptid
bound
receptor
protein
peptid
librari
use
find
diseasespecif
antigen
cell
organspecif
peptid
recent
use
affin
select
biopan
phagedisplay
peptid
librari
research
discov
molecul
express
tumor
blood
vessel
exclus
strategi
identifi
tumortarget
ligand
develop
ligandmedi
target
therapi
shown
figur
research
use
vivo
affin
select
phage
librari
identifi
peptid
interact
molecul
found
endothelia
tumor
ngr
peptid
motif
target
angiogen
blood
vessel
tumorhom
properti
ngr
motif
reli
recognit
isoform
select
express
within
tumor
blood
vessel
compar
nontarget
liposom
doxorubicin
caelyx
ngr
peptideconjug
caelyx
signific
improv
surviv
seen
clinic
relev
anim
model
neuroblastoma
ovarian
lung
cancer
anoth
peptid
found
recogn
blood
vessel
creat
tumor
normal
blood
vessel
sever
combin
immunodefici
scid
mice
bear
solid
tumor
sever
select
phage
clone
display
proserpro
motif
crucial
peptid
bind
tumor
neovasculatur
sever
tumor
home
peptid
found
bind
blood
vessel
surgic
specimen
human
cancer
also
found
home
tumor
tissu
differ
human
tumor
xenograft
confirm
vivo
home
assay
studi
found
greater
correl
increas
tumor
accumul
target
liposom
antitumor
efficaci
accumul
free
drug
drug
formul
nontarget
liposom
drug
deliveri
system
approv
market
liposom
lipidbas
formul
therapeut
molecul
link
polyethylen
glycol
peg
one
product
pegyl
liposom
doxorubicin
known
doxil
us
caelyx
europ
current
approv
treatment
aidsrel
kaposi
sarcoma
recurr
ovarian
cancer
north
america
europ
countri
metastat
breast
cancer
europ
liposomeencapsul
doxorubicin
found
significantli
improv
therapeut
index
doxorubicin
preclin
clinic
studi
import
advantag
pegyl
liposom
doxorubicin
heart
muscl
uptak
much
less
free
doxorubicin
one
studi
found
cardiotox
patient
receiv
cumul
dose
doxorubicin
free
doxorubicin
hand
limit
maximum
recommend
cumul
dose
colbern
et
al
found
activ
pegyl
liposom
doxorubicin
mgkg
almost
equival
free
doxorubicin
mgkg
mous
lewi
lung
carcinoma
one
clinic
studi
report
drug
circul
blood
stream
remain
encapsul
liposom
suggest
littl
liposom
drug
leak
circul
system
journey
tumor
tissu
hyperperm
tumor
vasculatur
key
factor
success
liposomedeliv
chemotherapi
agent
leaki
angiogen
tumor
vasculatur
estim
averag
pore
size
nm
pore
significantli
larger
gap
junction
found
normal
endothelium
typic
nm
wide
liposom
diamet
approxim
nm
small
enough
passiv
infiltr
tumor
endothelium
larg
enough
exclud
normal
endothelium
henc
select
extravas
tumor
interstiti
space
tissu
solid
tumor
vasculatur
becom
permeabl
particul
liposom
extravas
local
tissu
interstiti
space
addit
tumor
tissu
frequent
lack
effect
lymphat
drainag
mean
liposom
retain
longer
togeth
factor
increas
accumul
drug
within
tumor
refer
enhanc
permeabl
retent
epr
effect
maeda
et
al
eprmedi
passiv
tumor
target
liposom
increas
concentr
drug
solid
tumor
much
ten
time
compar
free
drug
passiv
target
liposom
drug
deliveri
system
disadvantag
normal
organ
uptak
liposom
lead
accumul
encapsul
drug
mononuclear
phagocyt
system
cell
liver
spleen
bone
marrow
may
present
hazard
tissu
exampl
increas
circul
time
drug
may
come
increas
toxic
induc
problem
handfoot
syndrom
mucos
hematolog
toxic
neutropenia
thrombocytopenia
leucopenia
therefor
ongo
research
aim
enhanc
tumor
sitespecif
action
liposom
attach
ligand
surfac
molecul
tumor
cell
tumor
vasculatur
process
call
activ
ligandmedi
target
liposom
disadvantag
passiv
pegyl
liposom
overcom
creat
ligandmedi
target
liposom
select
anticanc
activ
activ
anticanc
drug
enhanc
coupl
target
moieti
surfac
liposom
promot
select
bind
tumorassoci
antigen
facilit
deliveri
drugcontain
liposom
intend
cellular
site
drug
deliveri
system
higher
drugtocarri
ratio
immunoconjug
multival
present
ligand
increas
bind
avid
antibodi
bind
tumorspecif
antigen
far
yield
littl
success
drug
deliveri
system
solid
tumor
make
cancer
human
although
monoclon
antibodi
shown
clinic
potenti
tumor
target
agent
limit
larg
molecular
size
poor
tumor
penetr
immunogen
associ
immunoliposom
toxic
liver
bone
marrow
nonspecif
antibodi
uptak
limit
overcom
use
peptid
ligand
smaller
less
immunogen
molecul
easier
produc
manipul
furthermor
peptid
ligand
moder
affin
antigen
benefici
extrem
high
affin
antibodybind
impair
tumor
penetr
compar
antibodi
ligand
peptid
ligand
improv
tumor
penetr
decreas
mp
clearanc
conjug
liposom
increas
use
peptid
target
ligand
aid
use
phage
display
identifi
novel
ligand
figur
research
alreadi
produc
liposom
conjug
ligand
specif
target
tumor
cell
tumor
vasculatur
peptideconjug
liposom
three
main
compon
anticanc
drug
liposom
carrier
target
peptid
figur
remot
load
method
ammonium
sulfat
method
ph
gradient
method
encapsul
weak
base
doxorubicin
vinorelbin
liposom
effici
scheduledepend
drug
vinca
alkaloid
topotecan
also
potenti
candid
liposom
deliveri
extend
time
cancer
cell
expos
therapeut
level
drug
bioavail
pharmacodynam
liposomeencapsul
chemotherapeut
drug
must
consid
develop
deliveri
system
take
advantag
epr
effect
liposom
need
long
halfliv
drug
stay
within
carrier
long
possibl
blood
circul
accumul
diseas
tissu
liposom
local
solid
tumor
drug
contain
must
releas
becom
bioavail
rate
remain
therapeut
effect
period
time
rate
activ
drug
releas
tumor
cell
total
drug
concentr
tumor
tissu
critic
measur
actual
bioavail
liposom
drug
target
liposom
found
greater
therapeut
efficaci
passiv
liposom
drug
possibl
lack
intern
ligand
give
drug
greater
access
insid
tumor
cell
drug
deliveri
enhanc
liposomeattach
ligand
bind
select
intern
antigen
would
help
increas
concentr
drug
insid
tumor
tumorassoci
endotheli
cell
result
higher
drug
concentr
insid
cell
bind
intern
antigen
ligand
induc
receptormedi
endocytosi
liposom
endosom
compart
low
ph
liposom
break
releas
encapsul
drug
intracellular
space
figur
step
lead
higher
intracellular
drug
concentr
greater
destruct
inhibit
tumor
cell
studi
confirm
greater
cytotox
effect
produc
liposom
peptid
target
intern
antigen
enhanc
specif
improv
drug
bioavail
use
drugencapsul
liposom
ligand
target
tumor
blood
vessel
allow
us
destroy
tumor
blood
vessel
tumor
cell
mice
bear
human
cancer
xenograft
low
dose
peptideconjug
liposom
doxorubicin
found
markedli
inhibit
vascular
reduc
total
volum
weight
tumor
immunofluoresc
analysi
tumor
sever
studi
reveal
associ
signific
decreas
microvessel
densiti
increas
apoptosi
tumor
cell
tumorassoci
endotheli
cell
sever
damag
tumor
vasculatur
caus
peptideconjug
liposom
doxorubicin
throughout
tumor
suggest
improv
chemotherapeut
efficaci
nontarget
liposom
convent
drug
dual
action
may
produc
greater
durabl
anticanc
effect
found
use
simpl
antiangiogen
therapi
one
peptideconjug
liposom
deliv
ten
thousand
anticanc
drug
molecul
directli
target
tumor
cell
effici
effect
target
sustain
releas
drug
molecul
increas
maximum
toler
dose
mtd
cytotox
drug
dramat
lower
doselimit
toxic
turn
prevent
treatment
delay
discontinu
affin
target
ligand
may
allow
liposom
move
past
high
ifp
barrier
within
tumor
advanc
nanotechnolog
molecular
biolog
move
us
closer
develop
ideal
multifunct
smart
nanodrug
deliveri
system
use
variou
type
ligand
drug
base
kind
diagnosi
imag
therapi
need
smart
nanodrug
deliveri
system
allow
accur
specif
noninvas
diseas
treatment
earli
diagnosi
monitor
futur
combin
ligand
specif
bind
cancer
cell
includ
cancer
stem
cell
tumor
blood
vessel
multifunct
liposom
drug
deliveri
system
may
help
improv
effect
cancer
treatment
minim
side
effect
tradit
associ
chemotherapi
develop
highli
select
anticanc
drug
discrimin
tumor
cell
normal
cell
import
goal
current
oncolog
research
potenti
use
ligandconjug
liposomeencapsul
drug
target
tumor
cell
vasculatur
promis
peptid
specif
bind
tumor
target
coupl
peg
terminu
steric
stabil
liposom
subsequ
precis
deliv
chemotherapeut
agent
tumor
cell
blood
vessel
peptidemedi
liposom
target
vasculatur
new
gener
chemotherapi
deliveri
system
superior
pharmacokinet
control
biodistribut
efficaci
safeti
profil
